Old drug, new hope: niclosamide tested for tough childhood leukemia
NCT ID NCT05188170
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 39 times
Summary
This early-phase trial tests niclosamide, a drug previously used for tapeworm infections, combined with standard chemotherapy in 16 children whose acute myeloid leukemia (AML) has returned or not responded to treatment. The main goal is to find a safe dose and check for side effects. Researchers will also look for signs that the treatment is shrinking the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Stanford University
RECRUITINGPalo Alto, California, 94305, United States
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
niclosamide
What this could lead to
If it works, this could point toward a new treatment option for children with hard-to-treat AML.
What could go wrong
This is a very early Phase 1 trial with only 16 participants, so it may not lead to a proven therapy. There are also risks of serious side effects from the drug combination.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.